Emcure Q1 PAT Jumps 41% YoY

  Published 10 months ago

Emcure Pharma posted 41% YoY PAT growth to ₹215 crore in Q1, with strong gains across domestic and global markets.

  • Revenue rose 15.7% YoY to ₹2,101 crore, driven by domestic therapy growth and robust global performance.
  • International sales grew 22%, led by 42% RoW growth and strong launches in Canada (16.4%) and Europe (12.8%).
  • EBITDA grew 20.1% with 19.2% margins; strong product pipeline and Sanofi tie-up to drive future growth.

You might like these

Castrol Wins ₹4,131 Cr Tax Case

RailTel Bags Rs 259 Crore Orders for School Supplies in HP & Bihar

GST Cut Boosts Tractor Stocks

Vedanta Rises After J.P. Morgan Support

India Tightens Equity Derivatives Oversight

JSW Steel Q2 Profit Surges

Syrma & Dynabook: India Laptop Manufacturing Boost

News that matters the most ⚡